Momenta Pharmaceuticals, Inc. (MNTA) - NASDAQ
  • Jun. 18, 2015, 5:36 PM
    | Jun. 18, 2015, 5:36 PM | 4 Comments
  • Jun. 9, 2015, 10:55 AM
    • CVS Health (CVS -0.1%) initiated with Outperform rating and $115 (16% upside) price target by Macquarie.
    • Galapagos (GLPG -3%) initiated with Overweight rating and $73 (36% upside) price target by Morgan Stanley.
    • LifePoint Health (LPNT) initiated with Conviction Buy rating and $92 (25% upside) price target by Goldman Sachs.
    • BioMarin Pharmaceutical (BMRN -2.2%) initiated with Overweight rating and $150 (24% upside) price target by Barclays.
    • Universal Health Services (UHS +0.2%) initiated with Neutral rating and $140 (10% upside) price target by Goldman Sachs.
    • Amsurg (AMSG -0.5%) initiated with Buy rating and $81 (17% upside) price target by Goldman Sachs.
    • Momenta Pharmaceuticals (MNTA -2.6%) initiated with Buy rating and $26 (18% upside) price target by Stifel Nicolaus.
    • Actavis (ACT -0.6%) initiated with Outperform rating and $344 (16% upside) price target by Raymond James.
    | Jun. 9, 2015, 10:55 AM
  • May 19, 2015, 8:20 PM
    • Momenta Pharmaceuticals (NASDAQ:MNTA) prices its public offering of 7.25M shares of common stock at $19 per share. Underwriters over-allotment is an additional 1.0875M shares.
    • Today's close was $19.31.
    | May 19, 2015, 8:20 PM
  • May 18, 2015, 4:04 PM
    • Momenta Pharmaceuticals (NASDAQ:MNTA) commences a public offering of 7.25M shares of common stock. Underwriters over-allotment is an additional 1.0875M shares. Price and terms have yet to be announced.
    | May 18, 2015, 4:04 PM
  • May 1, 2015, 10:23 AM
    • Momenta Pharmaceuticals (MNTA +6.5%) Q1 results: Revenues: $8.6M (-20.4%); R&D Expense: $22.7M (-15.0%); SG&A: $7.9M (-32.5%); Operating Loss: ($22.1M) (+19.9%); Net Loss: ($21.9M) (+20.1%); Loss Per Share: ($0.40) (+24.5%); Quick Assets: $198.7M (+3.8%).
    • Q2 2015 Guidance: Net Cash Usage: ~$28M - $32M.
    | May 1, 2015, 10:23 AM
  • May 1, 2015, 8:01 AM
    • Momenta Pharmaceuticals (NASDAQ:MNTA): Q1 EPS of -$0.40 beats by $0.05.
    • Revenue of $8.56M (-20.6% Y/Y) misses by $3.17M.
    | May 1, 2015, 8:01 AM | 1 Comment
  • Apr. 30, 2015, 5:30 PM
    | Apr. 30, 2015, 5:30 PM | 5 Comments
  • Apr. 16, 2015, 1:07 PM
    • The FDA approves Sandoz's (NVS -0.1%) Abbreviated New Drug Application (ANDA) for once-daily Glatopa (glatiramer acetate) injection 20 mg/mL, a generic equivalent to Teva Pharmaceutical Industries' (TEVA -2.9%) Copaxone for the treatment of relapsing forms of multiple sclerosis.
    • Glatopa, the first approved substitutable generic to Teva's top seller, was developed under a collaboration between Sandoz and Momenta Pharmaceuticals (MNTA +13.5%). Under the terms of the collaboration agreement, Momenta is eligible to receive up to $140M in milestones, including $10M upon the approval of the ANDA and $10M upon the first commercial sale.
    • Copaxone generated $4.2B in sales for Teva the past four quarters, accounting for 21% of its revenues.
    | Apr. 16, 2015, 1:07 PM | 18 Comments
  • Feb. 17, 2015, 8:31 AM
    • Momenta Pharmaceuticals (MNTA -0.5%) Q4 results: Revenues: $21.2M (+65.6%); R&D Expense: $26.2M (-18.6%); SG&A: $11.1M (+2.8%); Operating Loss: ($16.1M) (+46.9%); Net Loss: ($16M) (+46.8%); Loss Per Share: ($0.31) (+47.5%).
    • FY2014 results: Revenues: $52.3M (+47.3%); R&D Expense: $106.5M (+2.4%); SG&A: $45.2M (+10.0%); Operating Loss: ($99.4M) (+9.3%); Net Loss: ($98.6M) (+9.0%); Loss Per Share: ($1.91) (+10.3%); Quick Assets: $191.5M (-22.1%).
    • Q1 2015 Guidance: Net Cash Usage: ~$30M.
    | Feb. 17, 2015, 8:31 AM
  • Feb. 17, 2015, 8:02 AM
    • Momenta Pharmaceuticals (NASDAQ:MNTA): Q4 EPS of -$0.31 misses by $0.05.
    • Revenue of $21.18M (+66.1% Y/Y) misses by $2.62M.
    | Feb. 17, 2015, 8:02 AM
  • Feb. 16, 2015, 5:30 PM
  • Feb. 3, 2015, 9:19 AM
    • Momenta Pharmaceuticals (NASDAQ:MNTA) will report Q4 and full-year results on February 17 before the open. The conference call will begin at 10:00 am ET.
    • Consensus views for Q4 and 2014 are losses per share of ($0.26) and ($1.82) on revenues of $23.8M and $56.9M, respectively.
    | Feb. 3, 2015, 9:19 AM
  • Dec. 1, 2014, 11:24 AM
    • The FDA grants Momenta Pharmaceuticals' (MNTA +2.7%) investigational oncology drug candidate, necuparanib, Fast Track status for the first-line treatment in combination with Abraxane (paclitaxel) and gemcitabine in patients with metastatic pancreatic cancer. Necuparanib is currently in Phase 2 development.
    • Fast Track designation allows for more frequent interactions with the FDA and a rolling review of the NDA.
    | Dec. 1, 2014, 11:24 AM
  • Nov. 5, 2014, 10:03 AM
    • Momenta Pharmaceuticals (MNTA -1.9%) Q3 results: Revenue: $9.3M (-13.9%); Operating expenses: $38.6M (+6.0%); Operating Loss: ($29.3M) (-14.0%); Net loss: ($29.1M) (-14.6%); Loss Per Share: $(0.56) (-12.0%); Quick Assets: $176.5M (-28.2%).
    • 2014 Guidance: Operating expenses: $30M - 32M from $28M - 30M.
    | Nov. 5, 2014, 10:03 AM
  • Nov. 5, 2014, 8:04 AM
    • Momenta Pharmaceuticals (NASDAQ:MNTA): Q3 EPS of -$0.56 misses by $0.13.
    • Revenue of $9.34M (-13.1% Y/Y) misses by $3.66M.
    | Nov. 5, 2014, 8:04 AM
  • Nov. 4, 2014, 5:30 PM
Company Description
Momenta Pharmaceuticals, Inc. is a biotechnology company, engages in the structural analysis of complex mixture drugs. The company focuses on discovering and developing medicines in three product areas: complex generics, biosimilars and novel therapeutics for oncology and autoimmune disease. The... More
Sector: Healthcare
Industry: Biotechnology
Country: United States